Overview
Resihance 40 mg contains Regorafenib, an oral multikinase inhibitor used in the treatment of certain types of advanced cancers. It targets several enzymes involved in tumor growth, angiogenesis (formation of blood vessels), and the tumor microenvironment. Regorafenib is commonly prescribed for metastatic colorectal cancer, advanced gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC) when other therapies have failed.





